M. Hussain

Circulating Endothelial Progenitor Cells in Multiple Myeloma: Implications and Significance Short title for running head: Circulating Endothelial Cells in Multiple Myeloma Scientific heading: Neoplasia Authors:

T. Özçelik, H. Akman, V. Vakil, 2004 .

A clinical trial of intravenous and intracavitary bleomycin

J. Horton, T. Cunningham, A. Wright, 1972, Cancer.

A phase II clinical trial with proteomic profiling of imatinib mesylate in patients with refractory or relapsed epithelial ovarian cancer (EOC).

S. Steinberg, E. Kohn, L. Liotta, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.

S. Steinberg, E. Kohn, L. Minasian, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial

D. Smith, D. Petrylak, D. Trump, 2005 .

Angiogenesis and metastasis.

E. Kohn, M. Hussain, Gregory J Sieczkiewicz, 2002, Cancer treatment and research.

Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer

S. Steinberg, E. Kohn, L. Minasian, 2010, Cancer.

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

S. Steinberg, E. Kohn, L. Minasian, 2007, Cancer.

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

S. Steinberg, E. Kohn, L. Minasian, 2007, Cancer.

Ten‐year follow‐up of a phase 2 study of dose‐intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor‐prognosis, advanced‐stage epithelial ovarian cancer

S. Steinberg, E. Kohn, L. Minasian, 2010, Cancer.